Clinical trial
Efficacy and Safety of Rivastigmine in Patients With Traumatic Brain Injury and Cognitive Impairment
NCT00171795 is registered in ClinicalTrials.gov with Novartis as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Efficacy and Safety of Rivastigmine in Patients With Traumatic Brain Injury and Cognitive Impairment
- Lead sponsor
- Novartis
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- November 30, 2002
- Completion date
- May 31, 2005
- Enrollment
- 67 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
traumatic brain injury